These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15298067)

  • 1. Drugs in development for Parkinson's disease.
    Johnston TH; Brotchie JM
    Curr Opin Investig Drugs; 2004 Jul; 5(7):720-6. PubMed ID: 15298067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs in development for Parkinson's disease: an update.
    Johnston TH; Brotchie JM
    Curr Opin Investig Drugs; 2006 Jan; 7(1):25-32. PubMed ID: 16425668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in the delivery of treatments for Parkinson's disease.
    Johnston TH; Fox SH; Brotchie JM
    Expert Opin Drug Deliv; 2005 Nov; 2(6):1059-73. PubMed ID: 16296809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
    Huot P; Fox SH; Newman-Tancredi A; Brotchie JM
    J Pharmacol Exp Ther; 2011 Oct; 339(1):2-8. PubMed ID: 21784889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.
    Pinna A; Wardas J; Simola N; Morelli M
    Life Sci; 2005 Nov; 77(26):3259-67. PubMed ID: 15979104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
    Jenner P
    Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for Parkinson's disease.
    Poewe W; Mahlknecht P; Jankovic J
    Curr Opin Neurol; 2012 Aug; 25(4):448-59. PubMed ID: 22772874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug selection and timing of initiation of treatment in early Parkinson's disease.
    Schapira AH; Olanow CW
    Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P
    Mov Disord; 2008; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs used to treat Parkinson's disease, present status and future directions.
    Abdel-Salam OM
    CNS Neurol Disord Drug Targets; 2008 Oct; 7(4):321-42. PubMed ID: 18991661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.